Olema Oncology announces participation in three upcoming investor conferences focused on breast cancer therapies.
Quiver AI Summary
Olema Oncology, Inc., a biopharmaceutical company specializing in targeted therapies for breast cancer, announced its participation in several upcoming investor conferences: the Evercore Healthcare Conference on November 30, 2026, the Citi Global Healthcare Conference on December 1, 2026, and the Piper Sandler Healthcare Conference on December 2, 2026. All presentations will be conducted as fireside chats and will be available via live webcasts on Olema's investor relations website. The company is focused on advancing its clinical pipeline, with its lead candidate palazestrant in Phase 3 trials and OP-3136 in a Phase 1 study. Olema is based in San Francisco and operates in Cambridge, Massachusetts.
Potential Positives
- Participation in major investor conferences, which can enhance visibility and attract potential investors.
- Presentation of Olema's innovative pipeline, including the lead product candidate, palazestrant, currently in Phase 3 clinical trials, highlighting the company's commitment to advancing breast cancer treatment.
- Showcasing Olema's development of new therapies, such as OP-3136, which demonstrates ongoing research efforts and potential for future growth.
Potential Negatives
- Participation in multiple investor conferences could indicate that the company is seeking to bolster investor confidence, suggesting existing concerns about its financial health or stock performance.
- The emphasis on the clinical development stage of its lead product candidate may highlight the risks associated with regulatory approvals and the uncertainty of future revenue generation.
- The lack of information about the current status of clinical trials may raise questions about the company's transparency and the progress of its drug development pipeline.
FAQ
What events is Olema Oncology participating in?
Olema Oncology will participate in the Evercore Healthcare Conference, Citi's Global Healthcare Conference, and Piper Sandler's Healthcare Conference.
When is Olema's investor conference schedule?
The conferences will be held on November 30, December 1, and December 2, 2026.
Where can I watch the Olema presentations?
Live webcasts and recordings will be available on Olema's investor relations website at ir.olema.com.
What is Olema's main focus?
Olema focuses on discovering and developing targeted therapies for breast cancer and other endocrine-driven cancers.
What is Olema's lead product candidate?
Olema's lead product candidate is palazestrant (OP-1250), currently in two Phase 3 clinical trials.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OLMA Insider Trading Activity
$OLMA insiders have traded $OLMA stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $OLMA stock by insiders over the last 6 months:
- CYRUS HARMON has made 0 purchases and 2 sales selling 25,000 shares for an estimated $291,162.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$OLMA Hedge Fund Activity
We have seen 103 institutional investors add shares of $OLMA stock to their portfolio, and 103 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 2,600,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $32,526,000
- JENNISON ASSOCIATES LLC removed 1,822,123 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $22,794,758
- CORMORANT ASSET MANAGEMENT, LP removed 1,750,000 shares (-44.9%) from their portfolio in Q2 2026, for an estimated $21,892,500
- POLAR CAPITAL HOLDINGS PLC removed 1,602,970 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $20,053,154
- FRANKLIN RESOURCES INC added 1,130,629 shares (+92.8%) to their portfolio in Q2 2026, for an estimated $14,144,168
- POINT72 ASSET MANAGEMENT, L.P. added 999,842 shares (+1406.1%) to their portfolio in Q2 2026, for an estimated $12,508,023
- AMERIPRISE FINANCIAL INC added 783,284 shares (+1365.5%) to their portfolio in Q2 2026, for an estimated $9,798,882
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$OLMA Analyst Ratings
Wall Street analysts have issued reports on $OLMA in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 09/14/2026
- JP Morgan issued a "Overweight" rating on 08/13/2026
- Citigroup issued a "Buy" rating on 08/11/2026
- HC Wainwright & Co. issued a "Buy" rating on 08/11/2026
To track analyst ratings and price targets for $OLMA, check out Quiver Quantitative's $OLMA forecast page.
$OLMA Price Targets
Multiple analysts have issued price targets for $OLMA recently. We have seen 4 analysts offer price targets for $OLMA in the last 6 months, with a median target of $41.0.
Here are some recent targets:
- Laura Prendergast from Stifel set a target price of $30.0 on 09/14/2026
- Anupam Rama from JP Morgan set a target price of $46.0 on 08/13/2026
- Yigal Nochomovitz from Citigroup set a target price of $59.0 on 08/11/2026
- Emily Bodnar from HC Wainwright & Co. set a target price of $36.0 on 08/11/2026
Full Release
SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
9
th
Annual Evercore Healthcare Conference
Date and Time: November 30, 2026 at 2:35 p.m. ET
Format: Fireside Chat
Location: Miami, FL
Citi's 2026 Global Healthcare Conference
Date and Time: December 1, 2026 at 1:00 p.m. ET
Format: Fireside Chat
Location: Miami, FL
Piper Sandler 38th Annual Healthcare Conference
Date and Time: December 2, 2026 at 1:30 p.m. ET
Format: Fireside Chat
Location: New York, NY
Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com .
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit
www.olema.com
.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]